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ABSTRACT 
The process of processing a drug and reaching to the market consists of various steps. In the early times of Drug Discovery, researchers faced 
with little or no Structure Activity Relationships information regarding any chemical moiety. Computer Aided Drug Designing (CADD) is a 
discipline allowing various aspects of research to merge together and stimulate each other. CADD acts as a tunnel in Drug Discovery and 
accelerates finding new lead compounds. The theoretical basis of CADD involves quantum mechanics and molecular modelling studies like 
Structure-based design, Ligand-based design, database searching and binding affinity. QSAR is structural descriptors of chemical compound to 
its biological activity. It is very important to find out relationships between molecular structure and useful properties and so Drug Discovery 
and Development get more complex. But automation of chemical synthesis and pharmacological screening provides a vast amount o f 
experimental data. 
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INTRODUCTION 
The pipeline of drug discovery from idea to market consists 
of seven stepsviz. disease selection, target selection, lead 
compound identification and leadoptimization, preclinical 
trial testing, clinical trial testing and pharmacological 
optimization. Compounds for testing are naturally obtained 
from plants, animals and microorganisms. These compounds 
can be rejected if found absence or low activity, existence of 
toxicity or carcinogenicity, complexity of synthesis, 
insufficient efficiency etc1. As a result, only about 1/100000 
investigated compounds are introduced in market. 
The process of Drug discovery and developing a new 
medicine is long, complex, risky and highly risky process. 
This is why, Computer Aided Drug Design (CADD) being 
widely used in Pharmaceutical Industry to accelerate this 
process. On an average, it takes 10-15 years and US$ 500-
800 million for introducing a new drug into market in which 
synthesis and testing of lead analogues are large 
contributors2.Computational tools are much easier to 
applyin hit to lead optimization to cover a wider range and 
whereby reducing the number of compounds must be 
synthesised and tested in vitro.The computational 
optimization involves structural based analysis of docking 
poses and energy profiles for hit analogues;ligand based 
screening, prediction of favourable affinity or optimizes drug 
metabolism, excretion and potential of toxicity3. The lower 
cost of CADD with respect to chemical synthesis and 
biological characteristics of compounds make more 
attractive to focus, reduce and diversify the chemical space4. 
However, most of the molecular discoveries are the results 
of an iterative in three – phase cycle of design, synthesis and 
test. Fig. 1 shows the steps in Drug discovery. 
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Fig. 1 Stages of Drug Discovery 
After analysing, the results from one interaction provide 
information and knowledge that gives initiation to the next 
cycle of discovery. The analysis stage has the common 
feature of construction of some models enabling the 
observed activity to be related to molecular structure5. 
These models are called as Quantitative Structure Activity 
Relationships (QSAR). The conventional process of Drug 
Discovery was all about blind screening approach which was 
time taking and laborious. This advantage of Conventional 
Drug Discovery led to the concept of Rational Drug 
Discovery in 1960’s. The knowledge of QSAR ushered in the 
beginning of CADD6-8.      
Software Used: - Some of the features used software for drug 
design and their salient features are as follows:- 
1. Affinity: - It is automated software, which uses energy 
of the ligand receptor complex to automatically find 
the best binding modes of the ligand to the receptor. 
2. AutoDock: - It consist of three separate programs- 
AutoDock 
AutoGrid 
AutoTors 
It provides an automated procedure for predicting the 
interaction of ligands with bio-molecular targets and help to 
narrow the conformational possibilities and in identification 
of the most suitable structure. 
3. Comb build: - It is a structure based drug design 
program which created to aid the design of 
combinational libraries. 
4. Dock Vision: -DockVision is a docking package created 
by scientists for scientists by including Monte Carlo, 
Genetic Algorithm and database screening docking 
algorithms. 
5. FRED:- It is an accurate and extremely fast, multi-
conformer docking programme which examines all 
possible poses within a protein active site, filtering for 
shape complementarity. 
6. FlexDack: - It is a simple, flexible docking of ligands 
into binding sites on proteins. 
7. FlexX: - It is a fast computer program for predicting 
protein ligand interaction. Its two main applications:- 
 Complex prediction. 
 Virtual screening. 
8. Glide: - This is a high throughput ligand-receptor 
docking for fast library screening. It is also a fast and 
accurate docking programme. 
9. Gold: - It calculates docking modes of small molecules 
into protein binding site which is based on generic 
algorithm for protein-ligand docking. 
10. Dock: - Dock generates many possible orientation of a 
putative ligand within a user selected region of a 
receptor structure. It also searches databases for DNA 
binding compounds. 
11. Hint: - It is a hydropathic interaction which translates 
the well-developed medicinal chemistry and QSAR 
formation of logP and hydrophobicity into a free 
energy interaction model for all bio-molecular systems 
based on the experimental data form solvent 
partitioning.  
12. Ligplot: - It is a program for automatically plotting 
protein-ligand interaction which generates schematic 
diagrams of protein-ligand interactions for a given PDB 
file. 
13. Situs: - It is a program package for modelling of atomic 
resolution structures into low resolution density maps. 
14. Vegs: - It calculates ligand-receptor interaction energy. 
15. Icm-Dock: - It provides access to the chemical 
information and a unique set of tools for accurate 
ligand-protein docking, peptide-protein docking and 
protein-peptide docking. 
16. GRAMM (Global range molecular matching):- This is an 
empirical approach to smoothing the intermolecular 
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energy functions by changing the range of the atom-
atom potentials. 
17. Bielefeld Protein Docking: - It detects geometrical and 
chemical complementarities between surfaces of 
proteins and estimates docking positions. 
18. Bigger: - It helps in bio-molecular complex generation 
with global evaluation and ranking. 
19. ClusPro: - It integrated approach to protein-protein 
docking. 
20. Ludi: - It fits molecules into the active site of a receptor 
by matching complementary polar and hydrophobic 
groups. 
21. Ludi/CAP: - It ensures synthetic feasibility of 
compounds proposed by ludi. 
22. DoT: - It is the daughter of TURNIP. Which is used for 
computation of the electrostatic potential energy 
between two proteins or other charged molecules? 
23. Haddock: - It is a high – ambiguity driven protein-
protein docking. 
24. Hex: - It is a protein docking and molecular 
superposition program. 
25. Racheal :-It is a real time automated combinatorial 
Heuristic enhancement of lead compounds.[3] 
The concept of QSAR is to convert the new compound into 
mathematically quantified and computerized. There are two 
assumptions made with respect to relationship between 
chemical structure and biological potency of compound9-10. 
First is that, quantitative measure can be derived from 
structural properties (physicochemical properties like 
partition coefficient in sub-structural as presence or absence 
of certain chemical features) significant to biological activity. 
Other is the relationship between biological activity and 
molecular property can be derived mathematically.Before 
designing any drug, it is important to know the feature an 
‘Ideal Drug ‘should have- 
 It must be safe and effective. 
 It should be absorbed orally. 
 It should have high bioavailability. 
 It should be metabolically stable. 
 It should has long half-life. 
 It should be non-toxic. 
 It should have minimum or no side-effect. 
 It should be selectively distributed to target tissues11-
13. 
Computer methods of Drug design works on the 
postulate that pharmacologically active compounds interact 
with macromolecules (mainly proteins) through- 
 Electrostatic forces 
 Hydrophobic Interaction 
 H-bond formation 
Which are mainly considered during analysis and prediction 
of interaction. For modelling of interaction between ligand 
and macromolecules, various methods of calculations are 
required. These studies are done by multiprocessor 
computers under UNIX management.[10] In developing new 
drug, it starts with designing of “ligands” based on how these 
are recognised by the target proteins to bind it. There is a 
powerful tool called “LIGBUILD” makes this in Brookheaven 
format. Performing experiment to know protein dynamics is 
expensive and time taking14-16. That’s why, computational 
tools of dynamics of molecule becomes important. 
Evaluation is done by approaching ‘score’ which is a tool to 
evaluate the binding affinity of protein-ligand complex with 
known 3D structure. There are many other criteria as well to 
screen the candidate molecules17. Permeability across the 
bio-membrane is very important.’ XLOGP’ is able to calculate 
logP (logarithm of partition coefficient of solute between 
Octanol and Water) of common Organic compounds. It can 
provide detailed hydrophobicity distribution information of 
molecule. ‘PLOP’ is another tool used to find logP values of 
peptides along with Molecular LipophilicityPotential (MLP) 
profile with known structure. Rational programs in Drug 
Design fall in one of the three categories18-19- 
1. Scanners 
2. Builders 
3. Hybrids 
 Scanners: These programs are used in screening of 
lead compounds. 
 Builders and Hybrids: These mainly used for de novo 
generation of lead compounds. The database contains 
fragments of chemical building blocks instead of 
complete compound which creates population of 
derivatives with compound receptor 
complementarity20-22. 
It has been 40 years since QSAR found its way practicing in 
Pharmaceutical Industry. QSAR involves recognising the 
molecule. The important properties are steric, electronic, 
lipophilic properties. 
QSAR models are necessary because:- 
 They are very fast 
 They reduce the number of animals used in 
experiment23. 
QSAR involves:- 
1. Conversion of molecular descriptors into mathematical 
descriptors which encapsulate the key properties of 
molecules relevant to activity or property being 
modelled. 
2. From a large number of descriptors, selecting the 
relevant descriptors. 
3. Molecular descriptors are mapped into properties. 
4. Models are validated to determine how predictive it 
is24. 
Considerations in QSAR:- 
1. The compounds should belong to congeneric series. 
2. They should have same mechanism of action. 
3. Biological activity should be same25. 
History of QSAR 
The first formulation of QSAR was published in 1868 by 
Crum-Brown and Feaserstating, the physiological activity 
(Ø) is expressed as function of the chemical structure(c)  
Φ = f (C) 
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After a few decades, Richet, Meyer and Overton found 
independently the linear relationship between lipophilicity 
(expressed as solubility or oil-water partition coefficient) 
and biological effects (like toxicity and narcotic activity. L. 
Hammett in1930’s correlated electronic properties of 
Organic acids and bases with their equilibrium constants 
and reactivity. The first steric parameters along with the 
way of separating polar, steric and resonance effects were 
introduced by Taft. Hammett and Taft together raised the 
mechanistic basis for developed QSAR paradigm by Hansch 
and Fujita to yield the linear Hansch equation and its many 
extended forms26-27. 
Log 1/C = aσ + bπ + ck ………………… Linear form 
Log 1/C = a log P – b (log P)2 + cσ + k …… Nonlinear form 
Where, 
C - Concentration required producing a standard response 
Log P - partition coefficient between 1-octanol and water 
σ - Hammet substituent parameter 
π - Relative hydrophobicity of substituents 
a, b, c, k - Model co-efficient 
Other methods were also developed to tackle this structure 
activity questions. Free-Wilson equation is described as  
BA = Σ a i x i + u 
Where BA is the biological activity, u is the average 
contribution of the parentmolecule, and a i is the 
contribution of each structural feature; xi denotes 
thepresence x i = 1 or absence x i = 0 of a particular 
structural fragment. 
Limitations of this equation led the Fujita Ban equation to be 
more sophisticated. The equation as follows  
Log BA = Σ G i X i + u 
u is defined as the calculated biological activity value of the 
un-substituted parentcompound of a particular series. G i 
represents the biological activity contribution ofthe 
substituents, whereas X i is ascribed with a value of one 
when the substituent ispresent or zero when it is absent. 
The chemical information about molecular structure 
encoded by mathematical procedure is explained in terms of 
numerical representation called Molecular descriptors. The 
information content depends on two major factors28- 
 The molecular representation of compounds. 
 The algorithm which is used for calculation of the 
descriptors. 
There are three major types of parameters initially 
suggested- 
 Hydrophobic 
 Electronic 
 Steric 
Software’s used in Molecular Descriptors:- 
 Dragon 
 GAUSSSIAN 
 Hyperchem 
 CODESSA 
 MOE[14] 
QSAR methods are classified as:- 
1. Based on dimensionality 
 1D QSAR: It correlates activity with molecular properties 
like pka, log P etc. 
 2D QSAR: It correlates activity with structural patterns 
without taking 3D representation. 
 3D QSAR: It correlates activity with non – covalent 
interaction fields surrounding molecule. 
 4D QSAR: It includes ensemble of ligand configuration in 
3D QSAR. 
 5D QSAR: It represents different Induced-fit models in 
4D QSAR. 
 6D QSAR: It further incorporates different solvation 
methods in 5D QSAR. 
 Based on the type of chemometric methods. 
2. Depending upon type of correlation technique 
employed, QSAR methods are classified as 
followed:- 
 Linear methods : Include Linear Regression (LR), 
Multiple Linear Regression(MLR), Partial Least 
Squares (PLS) and Principal Component 
Analysis/Regression(PCA/PCR) 
 Non-Linear methods: It consists of artificial neural 
networks (ANN), K-Nearest Neighbours (KNN) and 
Baysian Neural Nets29. 
Limitations of QSAR 
1. Sometimes, the activity measured is inaccurate. 
2. 3D components in terms of physicochemical properties 
are difficult to express. 
3. It is difficult to study chiral compounds30. 
CONCLUSION  
Approaches used in CADD cannot replace the experimental 
tests. The purpose of CADD is to generate the hypothesis of 
probable new compounds and their interaction with targets. 
These methods can reduce the number of new compounds 
needed to be synthesised so capable to decrease time-
consuming and financial expenses in developing new drug. It 
is been accepted globally that QSAR based on well-
established principles of statistics is valuable medical tool 
whose application range from explain Structure Activity 
Relationships quantitatively and retrospectively to 
endowing synthetic guidance leading to logical and 
experimentally testable hypothesis. 
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